@CandelTx Candel Therapeutics

Candel Therapeutics posts on X about $cadl, ceo, we are, advance the most. They currently have [---] followers and [---] posts still getting attention that total [---] engagements in the last [--] hours.

Engagements: [---] #

Mentions: [--] #

Followers: [---] #

CreatorRank: [---------] #

Social Influence

Social category influence stocks 64.55% finance 10% exchanges 2.73% travel destinations 1.82% financial services 1.82% countries 0.91%

Social topic influence $cadl #2, ceo 15.45%, we are 13.64%, advance 8.18%, icymi 5.45%, poster 5.45%, release 4.55%, future 4.55%, company 4.55%, financial 4.55%

Top accounts mentioned or mentioned by @paulpetertak @nasdaq @citeline @sitcancer @routeco145 @nnchamber @jefferies @urologytimes @pharmavoice @ascos @westorg @charuaggarwalmd @penn @jpmorgan @eachiocca @wcvb @longwoodleaders @biocentury @medcitynews @fiercebiotech

Top assets mentioned Candel Therapeutics, Inc. (CADL) Trinity Capital Inc. (TRIN)

Top Social Posts

Top posts by engagements in the last [--] hours

"This #CancerPreventionMonth we honor the power of research education and early action in fighting cancer. Our off-the-shelf multimodal immunotherapies harness the immune system to fight cancer. Together we're working to bring new treatment options to those who need them"
X Link 2026-02-13T15:00Z [---] followers, [---] engagements

"Congratulations to our very own Dr. Estuardo Aguilar-Cordova for being picked by @nnchamber as one of the [--] Most Influential Business People of Color #Immunotherapy #oncology #GMCI https://www.nnchamber.com/bpoc-list/estuardo-aguilar-cor https://www.nnchamber.com/bpoc-list/estuardo-aguilar-cor"
X Link 2020-11-14T23:17Z [---] followers, [--] engagements

"Pharma veteran and renowned immunologist @paulpetertak has joined Candel as our new CEO. Were also expanding our leadership team with new appointments including CFO CBO and CRO. Get the full details in our press release: https://www.businesswire.com/news/home/20201208005304/en/Candel-Therapeutics-Appoints-Pharma-Veteran-and-Immunologist-Paul-Peter-Tak-M.D.-Ph.D.-as-Chief-Executive-Officer-Expands-Leadership-Team-With-Chief-Financial-Officer-Chief-Business-Officer-and-Chief-Regulatory-Officer-Appointments"
X Link 2020-12-08T13:10Z [---] followers, [--] engagements

"Were excited to join the @Nasdaq family Now #NasdaqListed and trading: $CADL. Learn more about our IPO here: https://bit.ly/3i5UcnL https://bit.ly/3i5UcnL"
X Link 2021-07-28T18:19Z [---] followers, [--] engagements

"Today marks our one year anniversary on @Nasdaq We're extremely proud and grateful for our team members and supporters who helped us achieve this important milestone. Together we can work to create a better future for people diagnosed with cancer"
X Link 2022-07-27T16:04Z [---] followers, [--] engagements

"We joined renowned #oncology experts for our R&D Day and provided an extensive update on our viral #immunotherapy pipeline including new #data from our #NSCLC and #HGG programs. Read highlights in the PR and view the event recording here: https://bit.ly/3UGwheG https://bit.ly/3UGwheG"
X Link 2022-12-07T19:29Z [---] followers, [--] engagements

"Watch our CEO @paulpetertak discuss the promising phase 2a results of CAN-2409 in pancreatic cancer showing median overall survival of [----] months vs [----] months in the control group with [--] patients still alive after extended follow-up. $CADL https://www.proactiveinvestors.com/companies/news/1067175/candel-therapeutics-ceo-discusses-promising-phase-2-pancreatic-cancer-trial-results-icymi-1067175.html https://www.proactiveinvestors.com/companies/news/1067175/candel-therapeutics-ceo-discusses-promising-phase-2-pancreatic-cancer-trial-results-icymi-1067175.html"
X Link 2025-04-21T15:34Z [---] followers, [----] engagements

"We're pleased to announce Candel's participation in two investor conferences. We look forward to discussing our innovative viral immunotherapies & clinical progress with the investment community. See todays release for details: $CADL https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-present-upcoming-investor-conferences https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-present-upcoming-investor-conferences"
X Link 2025-05-06T12:31Z [---] followers, [----] engagements

"Today we announced presentations at [--] upcoming investor conferences in September Join us in Boston & NYC as we discuss our viral immunotherapy pipeline including CAN-2409s phase [--] success in prostate cancer. Details: $CADL https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-participate-upcoming-investor-conferences https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-participate-upcoming-investor-conferences"
X Link 2025-08-28T13:02Z [---] followers, [----] engagements

"Were participating in the H.C. Wainwright Annual Global Investment Conference. With $100.7 million in cash as of June [--] [----] were well-positioned to fund operations into Q1 [----] and execute on key value-creating milestones. $CADL #HCWainwright https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-participate-upcoming-investor-conferences https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-participate-upcoming-investor-conferences"
X Link 2025-09-08T13:05Z [---] followers, [----] engagements

"Well be at #SITC2025 Presenting posters on our enLIGHTEN platform and CAN-2409 in NSCLC plus our CEO @paulpetertak will speak on our phase [--] prostate cancer data. See the curtain raiser: #Immunotherapy #ProstateCancer #NSCLC https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-present-sitc-2025-annual-meeting https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-present-sitc-2025-annual-meeting"
X Link 2025-10-03T13:10Z [---] followers, [---] engagements

"October is National Healthy Lung Month. Our CAN-2409 NSCLC program shows promise: [----] months median survival vs 9.8-11.8 months with standard treatment in patients with progressive disease. Lung cancer claims 1.8M+ lives annually. Every breakthrough matters. #HealthyLungMonth"
X Link 2025-10-13T14:00Z [---] followers, [---] engagements

"We are pleased to announce Dr. Bali Pulendran joins Candels Research Advisory Board. Dr. Pulendran is a leading systems immunology expert and Professor at Stanford. $CADL #Advisory https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-appoints-leading-systems-immunology-expert https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-appoints-leading-systems-immunology-expert"
X Link 2025-10-16T12:09Z [---] followers, [----] engagements

"November is #LungCancerAwareness Month. Our CAN-2409 NSCLC program shows promise: [----] months median survival in ICI-refractory patients vs [--] months with standard of care chemotherapy. Lung cancer claims 1.8M+ lives annually. Every breakthrough matters. https://candeltx.com/patients/#step-25 https://candeltx.com/patients/#step-25"
X Link 2025-11-03T15:39Z [---] followers, [----] engagements

"Well be sharing data from our CAN-2409 program in NSCLC & and our enLIGHTEN Discovery Platform. Our CEO @paulpetertak will give a presentation on the phase [--] clinical trial of CAN-2409 in prostate cancer. More details: https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-showcases-immunotherapy-leadership-sitc-2025 https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-showcases-immunotherapy-leadership-sitc-2025"
X Link 2025-11-04T14:16Z [---] followers, [----] engagements

"#ICYMI - We secured a $130M term loan facility with Trinity Capital strengthening our runway through key milestones: - BLA submission Q4 [----] - Commercial launch prep - NSCLC pivotal studies Q2 [----] $CADL https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-enters-130-million-term-loan-facility https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-enters-130-million-term-loan-facility"
X Link 2025-11-11T15:00Z [---] followers, [----] engagements

"Our CEO @paulpetertak will share the latest corporate updates at the @Jefferies London Healthcare Conference this week. See the details here: $CADL #JefferiesHealthcare https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-present-jefferies-global-healthcare-0 https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-present-jefferies-global-healthcare-0"
X Link 2025-11-17T15:01Z [---] followers, [----] engagements

"Were hosting a Virtual R&D Day to discuss our cancer immunotherapy pipeline. The #event will feature insights from leading experts as we discuss the future of #cancer treatment. $CADL https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-host-virtual-rd-event-december-5-2025 https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-host-virtual-rd-event-december-5-2025"
X Link 2025-12-02T15:01Z [---] followers, [----] engagements

"#ICYMI - Our Q3 financial results highlighted the significant progress across our cancer immunotherapy pipeline. From clinical advancements to strategic financing were positioning Candel for continued growth. Read more here: #CADL https://www.proactiveinvestors.com/companies/news/1082445/candel-therapeutics-highlights-3q-milestones-across-cancer-immunotherapy-pipeline-1082445.html https://www.proactiveinvestors.com/companies/news/1082445/candel-therapeutics-highlights-3q-milestones-across-cancer-immunotherapy-pipeline-1082445.html"
X Link 2025-12-08T15:00Z [---] followers, [----] engagements

"Dr. Glen Gejerman spoke to @UrologyTimes about Candels phase [--] trial results for CAN-249 in localized intermediate- to high-risk prostate cancer presented at ASTRO [----]. Tune into this insightful video to hear more. https://www.urologytimes.com/view/glen-gejerman-md-highlights-phase-3-data-on-can-2409-in-localized-prostate-cancer https://www.urologytimes.com/view/glen-gejerman-md-highlights-phase-3-data-on-can-2409-in-localized-prostate-cancer"
X Link 2025-12-10T15:00Z [---] followers, [----] engagements

"As [----] draws to a close we reflect on what an incredible year it has been. Were grateful for our dedicated team supportive partners and the patients who inspire our mission every day. Wishing everyone peace joy and continued optimism in the fight against cancer"
X Link 2025-12-23T15:59Z [---] followers, [---] engagements

"Next week our executive team will be in San Francisco for the J.P. Morgan Healthcare Conference. We look forward to connecting with industry leaders and the investor community. Hope to see you there #JPM2026 #Healthcare #Biotech $CADL"
X Link 2026-01-06T15:00Z [---] followers, [----] engagements

"NSCLC remains challenging to treat. Our viral immunotherapy CAN-2409 showed encouraging results in phase [--] achieving [--] months median overall survival vs. [--] months reported in the literature for second-line chemotherapy. Next is phase [--] trial initiation in Q2 [----]. $CADL"
X Link 2026-01-27T15:00Z [---] followers, [----] engagements

"Our phase [--] trial of CAN-2409 in intermediate-to-high-risk localized prostate cancer showed a 30% improvement in disease-free survival and 80% complete pathological response vs. 64% in controls. BLA submission planned for Q4 [----]. $CADL https://candeltx.com/ https://candeltx.com/"
X Link 2026-01-29T15:00Z [---] followers, [----] engagements

"Thank you to @PharmaVoice for including our CEO @paulpetertak among industry leaders sharing their outlook for pharma in [----]. Dr. Tak shares his perspective on why adaptability will define successful commercialization strategies moving forward. https://www.pharmavoice.com/news/pharma-crystal-ball-2026-predictions-regulations-policy-market/808688/ https://www.pharmavoice.com/news/pharma-crystal-ball-2026-predictions-regulations-policy-market/808688/"
X Link 2026-02-02T15:00Z [---] followers, [----] engagements

"This #WorldCancerDay our commitment remains clear: developing innovative immunotherapies that harness each patients own immune system to fight cancer. Were advancing two clinical-stage immunotherapy platforms targeting some of cancers toughest challenges"
X Link 2026-02-04T15:00Z [---] followers, [---] engagements

"#TBT to last month when Candel was honored with the [----] Scrip Award for Best Oncology R&D Advance This recognition celebrates our successful phase [--] study of CAN-2409 in localized prostate cancer. Thank you to @Citeline for this honor. $CADL https://citeline.com/en/awards/scripawards https://citeline.com/en/awards/scripawards"
X Link 2026-01-09T15:00Z [---] followers, [----] engagements

"Read this article highlighting our viral immunotherapy approach and promising clinical results across multiple solid tumors. It covers our positive phase [--] data in prostate cancer and our plans to file a BLA for CAN-2409 in late [----]. $CADL https://www.nature.com/articles/d43747-025-00101-6 https://www.nature.com/articles/d43747-025-00101-6"
X Link 2026-01-12T15:00Z [---] followers, [----] engagements

"#ICYMI - Our Virtual R&D Day brought together immunotherapy legends alongside leading oncologists to discuss our viral immunotherapy platform CAN-2409s path to BLA submission and updates across our clinical pipeline. Watch the full webcast $CADL https://ir.candeltx.com/events/event-details/candel-therapeutics-host-virtual-rd-event https://ir.candeltx.com/events/event-details/candel-therapeutics-host-virtual-rd-event"
X Link 2026-01-21T15:00Z [---] followers, [----] engagements

"Were excited to share that our Chief Scientific Officer Francesca Barone will be presenting at the 7th Glioblastoma Drug Development Summit next week in Boston. #Glioblastoma #CancerResearch https://glioblastoma-drugdevelopment.com/speaker/francesca-barone/ https://glioblastoma-drugdevelopment.com/speaker/francesca-barone/"
X Link 2026-02-10T15:00Z [---] followers, [---] engagements

"We are looking forward to @ASCO's Genitourinary Cancers Symposium later this month. We're attending to hear the latest in genitourinary oncology and network with colleagues across the community advancing care for patients. #GU26 #Cancer"
X Link 2026-02-18T18:27Z [---] followers, [---] engagements

"#ICYMI Earlier this month we announced our sponsorship of @WESTorg a group that helps early to mid-career women develop business & leadership skills and grow professional networks. At Candel we are committed in our support for #women leaders in #STEM: https://bit.ly/3rmXcOe https://bit.ly/3rmXcOe"
X Link 2021-03-25T15:06Z [---] followers, [--] engagements

"#ICYMI Candel is now part of the @Nasdaq family Were excited to share this moment with our dedicated employees and look forward to continuing our purpose to save extend and improve the lives of patients through oncolytic viral #immunotherapies. #IPO $CADL"
X Link 2021-08-03T16:00Z [---] followers, [--] engagements

"Congratulations to our incredible team on this milestone today We are excited to ring in a new era for Candel and take the next step as a public company"
X Link 2021-08-20T13:27Z [---] followers, [--] engagements

"Lead investigator @CharuAggarwalMD and Candel present phase [--] #data on CAN-2409 showing cytotoxic T cell response & disease control in patients with #NSCLC at #ASCO22. View our poster here: https://www.candeltx.com/wp-content/uploads/news/Candel-ASCO-2022.pdf https://www.candeltx.com/wp-content/uploads/news/Candel-ASCO-2022.pdf"
X Link 2022-06-06T16:12Z [---] followers, [--] engagements

"We hope to shine a light on the challenges faced patients w/ #ProstateCancer & provide support through new promising investigational treatment options. Learn how Luis and the team leverage their expertise to positively impact the community: #ProstateCancerAwarenessMonth"
X Link 2022-09-19T16:41Z [---] followers, [--] engagements

"We've partnered w/ @Penn Center for Cellular Immunotherapies to study novel viral #immunotherapies in combo w/ CAR-T cell therapies for #solidtumors via our enLIGHTEN Discovery Platform. Learn more about the partnership & our newly debuted platform: https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-partners-university-pennsylvanias-center https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-partners-university-pennsylvanias-center"
X Link 2022-10-26T12:06Z [---] followers, [--] engagements

"Save the date On December [--] our leadership team will join renowned experts in #oncology for our virtual R&D Day where well conduct an in-depth review of our viral #immunotherapy platforms and late-stage clinical pipeline. Stay tuned for further details"
X Link 2022-11-21T17:36Z [---] followers, [--] engagements

"During our R&D Day on Dec. [--] we will provide an overview of our viral #immunotherapy approach and #oncology pipeline including new data from our phase [--] clinical trial of CAN-2409 with anti-PD-1 agents in patients with late-stage #NSCLC. Read more here: https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-host-virtual-rd-day-december-6-2022 https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-host-virtual-rd-day-december-6-2022"
X Link 2022-11-29T13:02Z [---] followers, [--] engagements

"Candel has arrived in #SanFrancisco for the 41st Annual @jpmorgan Healthcare Conference to discuss our exciting pipeline of viral #immunotherapies with investors and industry colleagues. Let us know if youll be at #JPM23 and would like to connect"
X Link 2023-01-09T18:41Z [---] followers, [----] engagements

"We are pleased to report updated data from our phase [--] clinical trial of CAN-2409 in non-small cell lung cancer. These initial data demonstrate an encouraging number of survivors and a favorable safety profile for CAN-2409. Read more here: https://bit.ly/48qstGB https://bit.ly/48qstGB"
X Link 2023-09-26T12:07Z [---] followers, [----] engagements

"Watch our Principal Investigator @EAChiocca discuss the newest CAN-3110 scientific publication in Nature. We are honored to see the progress of our investigational viral immunotherapy and look forward to developing it in the future. Read the publication: https://bit.ly/3s0t55v Honored to be featured this evening on @WCVB NewsCenter [--] at [--] highlighting our teams advances on treating #Glioblastoma. 📸🧠 https://t.co/vfT9304Kid https://bit.ly/3s0t55v Honored to be featured this evening on @WCVB NewsCenter [--] at [--] highlighting our teams advances on treating #Glioblastoma. 📸🧠"
X Link 2023-10-21T00:44Z [---] followers, [----] engagements

"President and CEO Paul Peter Tak MD PhD FMedSci discussed Candels development of multimodal biological immunotherapies to fight cancer and potentially alter the future of cancer immunotherapy in the below interview with Healthcare Future. https://bit.ly/3wzoJ7p https://bit.ly/3wzoJ7p"
X Link 2024-02-27T21:33Z [---] followers, [---] engagements

"We are pleased to share that we will unveil the second candidate from our enLIGHTEN Discovery Platform in a presentation at #AACR2024. Learn more about the presentation here: https://bit.ly/49EDfta https://bit.ly/49EDfta"
X Link 2024-03-05T21:42Z [---] followers, [---] engagements

"Brain science is critical to help lead healthier & more productive lives. At $CADL we know the importance of brain science and are developing our multimodal biological immunotherapy candidate CAN-3110 as a potential treatment for brain cancer. #BrainAwarenessWeek"
X Link 2024-03-11T13:00Z [---] followers, [---] engagements

"We are pleased to share that two abstracts were accepted for presentation at #ASCO2024. Presentations will highlight ph [--] topline OS data for CAN-2409 in NSCLC and a trials in progress update on the ph 1b trial of CAN-3110 in recurrent high-grade glioma. https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-announces-upcoming-presentations-2024-asco https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-announces-upcoming-presentations-2024-asco"
X Link 2024-04-25T12:10Z [---] followers, [----] engagements

"In honor of National #VolunteerMonth Candel is celebrating the power of giving back. Whether it's lending a hand at a soup kitchen mentoring youth or cleaning up parks every act makes a difference. Let's inspire kindness & compassion together #NationalVolunteerMonth"
X Link 2024-04-26T13:00Z [---] followers, [---] engagements

"We are seeing steady advancement across our pipeline of clinical and preclinical programs and are excited for whats to come. Learn about our Q1 progress and anticipated plans for the rest of the year in our Q1 [----] financial press release: https://bit.ly/44Ii9IH https://bit.ly/44Ii9IH"
X Link 2024-05-14T12:06Z [---] followers, [----] engagements

"We will present positive data from the P2 trial of CAN-2409 in NSCLC demonstrating a mOS of [----] months compared to published results of mOS of [----] months observed in a similar historical control patient population #ASCO2024. Read more https://bit.ly/4bRlBTK https://bit.ly/4bRlBTK"
X Link 2024-05-24T12:00Z [---] followers, [----] engagements

"We are pleased that the US FDA has granted Orphan Drug Designation to CAN-3110 for the treatment of rHGG. This designation builds on the momentum of the Fast Track Designation & reinforces the potential of CAN-3110 as a treatment option for rHGG patients. https://bit.ly/3KHNQZD https://bit.ly/3KHNQZD"
X Link 2024-05-30T12:04Z [---] followers, [----] engagements

"We presented a poster with positive data from the P2 trial of CAN-2409 in #NSCLC demonstrating a mOS of [----] months compared to published results of mOS of [----] months observed in a similar historical control patient population at #ASCO2024. https://bit.ly/45bwIow https://bit.ly/45bwIow"
X Link 2024-06-03T20:46Z [---] followers, [----] engagements

"#ICYMI the $CADL team hosted a breakfast panel at #ASCO2024 to review their highly anticipated poster presentation highlighting positive overall survival data from the phase [--] trial of CAN-2409 in #NSCLC. Listen to the event replay here: https://bit.ly/3wQANli https://bit.ly/3wQANli"
X Link 2024-06-04T18:14Z [---] followers, [----] engagements

"President and CEO @paulpetertak MD PhD FMedSci will moderate a panel discussion with fellow life Science CEOs on Managing the Runway at the @LongwoodLeaders Spring MIT conference on Tues June 18th at 10:50 a.m. ET. Learn more here: https://bit.ly/45DSAZX https://bit.ly/45DSAZX"
X Link 2024-06-14T13:00Z [---] followers, [---] engagements

"President and CEO @paulpetertak MD PhD FMedSci will discuss the latest company updates from $CADL at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference on Tuesday June [--] [----] at 3:00 p.m. ET. Listen to the discussion here: https://bit.ly/3OHUqm0 https://bit.ly/3OHUqm0"
X Link 2024-06-21T13:00Z [---] followers, [---] engagements

"Wishing everyone a fun and safe 4th of July holiday. Happy Independence Day #IndependenceDay #4thofJuly"
X Link 2024-07-04T13:00Z [---] followers, [---] engagements

"Glioblastoma Awareness Day is dedicated to raising awareness for the most common and deadliest type of brain cancer. At $CADL were developing our viral immunotherapy candidate CAN-3110 as a potential treatment for glioblastoma. https://bit.ly/3Y84GbL https://bit.ly/3Y84GbL"
X Link 2024-07-17T20:06Z [---] followers, [----] engagements

"1 in [--] people in the U.S. will be diagnosed with lung cancer in their lifetime. At $CADL we are committed to developing our viral immunotherapy CAN-2409 as an innovative promising treatment for those suffering from lung cancer. #WorldLungCancerDay https://bit.ly/4bRlBTK https://bit.ly/4bRlBTK"
X Link 2024-08-01T13:00Z [---] followers, [----] engagements

"$CADL Interim CFO Charles Schoch and VP of Investor Relations and Business Development Ted Jenkins will participate in the 44th Annual Canaccord Genuity Growth Conference taking place in Boston MA Aug 13-14th. Be sure to connect if youre attending the conference"
X Link 2024-08-08T13:00Z [---] followers, [---] engagements

"It is estimated that there will be approx. 299k new cases of #prostatecancer cases in the United States in [----]. At $CADL we're advancing our viral immunotherapy CAN-2409 designed to empower the immune system to fight cancer including #prostatecancer more effectively"
X Link 2024-09-05T13:00Z [---] followers, [----] engagements

"President and CEO @paulpetertak MD PhD FMedSci will discuss the latest company updates from Candel in a presentation at the H.C. Wainwright Annual Global Investment Conference. Listen to the presentation available on-demand here: https://bit.ly/3OHUqm0 https://bit.ly/3OHUqm0"
X Link 2024-09-09T13:00Z [---] followers, [---] engagements

"President and CEO @paulpetertak MD PhD FMedSci will chair a panel with other experts to discuss the improvements and new approaches to treating autoimmune and inflammatory diseases at the @BioCentury Grand Grounds. Learn more: https://bit.ly/3AFx6QJ https://bit.ly/3AFx6QJ"
X Link 2024-09-11T13:00Z [---] followers, [---] engagements

"On #WorldCancerResearchDay we honor the relentless pursuit of innovation in the fight against cancer. We're developing 2nd generation viral immunotherapies to empower the immune system to combat cancer. Join us as we push the boundaries of science and bring new hope. #WCRD2024"
X Link 2024-09-24T13:00Z [---] followers, [---] engagements

"We're committed to improving outcomes for #prostatecancer patients. CEO @paulpetertak discusses the need for better early-stage disease treatments & shares his thoughts on patient-centered innovation & the future of prostate cancer care in @MedCityNews. https://medcitynews.com/2024/09/prostate-cancer-management-we-need-better-options-for-early-stage-disease/ https://medcitynews.com/2024/09/prostate-cancer-management-we-need-better-options-for-early-stage-disease/"
X Link 2024-10-03T14:15Z [---] followers, [---] engagements

"Our team is presenting a poster on CAN-3110s activity in a model of #melanoma at @sitcancer 39th Annual Meeting See the details here: #SITC24 $CADL https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-present-preclinical-data-therapeutic https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-present-preclinical-data-therapeutic"
X Link 2024-10-04T13:15Z [---] followers, [----] engagements

"Only 15-40% of advanced #NSCLC patients respond to standard ICIs. This #HealthyLungMonth we're highlighting the need for new treatments. Candel is testing CAN-2409 a viral immunotherapy showing promise in progressive disease despite ICI treatment. https://www.candeltx.com/patients/#step-25 https://www.candeltx.com/patients/#step-25"
X Link 2024-10-10T15:00Z [---] followers, [---] engagements

"President and CEO @paulpetertak MD PhD FMedSci shares insights on our CAN-3110 clinical program for recurrent #glioblastoma with DocWire News. Watch to learn more. $CADL https://docwirenews.com/post/paul-peter-tak-ceo-of-candel-therapeutics-discusses-the-treatment-of-glioblastoma https://docwirenews.com/post/paul-peter-tak-ceo-of-candel-therapeutics-discusses-the-treatment-of-glioblastoma"
X Link 2024-10-17T12:59Z [---] followers, [----] engagements

"Over [---] million Americans are living with a #braintumor. Brain Tumor Awareness Week is dedicated to raising #awareness about the challenges faced by those diagnosed highlighting the need for specialized responses and for increased research efforts. https://theibta.org/awareness-raising/ibtaw-toolkit/ https://theibta.org/awareness-raising/ibtaw-toolkit/"
X Link 2024-10-29T14:00Z [---] followers, [---] engagements

"We're presenting preclinical data on CAN-3110 in a #melanoma model at #SITC24 Our poster will highlight: Potent antitumor activity Immune activation Potential expansion beyond high-grade glioma More details: $CADL #CancerResearch @sitcancer https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-present-preclinical-data-sitc-annual-meeting https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-present-preclinical-data-sitc-annual-meeting"
X Link 2024-11-05T14:09Z [---] followers, [----] engagements

"Excited to present our #SITC24 poster showing CAN-3110's promising activity in melanoma models - potentially expanding from high-grade glioma to #melanoma targeting nestin+ tumors. $CADL #CancerResearch #Immunotherapy @sitcancer https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-present-preclinical-data-sitc-annual-meeting https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-present-preclinical-data-sitc-annual-meeting"
X Link 2024-11-08T14:07Z [---] followers, [---] engagements

"We are seeing steady advancement across our pipeline and look forward to continued momentum as we head into [----]. Learn about our Q3 progress and anticipated plans for the rest of the year in our Q3 [----] financial press release: $CADL https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-reports-third-quarter-2024-financial-results https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-reports-third-quarter-2024-financial-results"
X Link 2024-11-14T13:10Z [---] followers, [----] engagements

"Our phase 2b #ProstateCancer trial asks: Can CAN-2409 administration stop disease progression in patients with low/intermediate risk prostate cancer who are undergoing active surveillance Learn more: $CADL #ClinicalTrials https://www.candeltx.com/pipeline/ https://www.candeltx.com/pipeline/"
X Link 2024-11-19T15:25Z [---] followers, [----] engagements

"This #WorldPancreaticCancerDay were highlighting our ph [--] clinical trial of CAN-2409 + standard care (SoC) in pancreatic cancer. Patients achieved estimated [----] months median survival in the CAN-2409 + SoC group vs [----] months in the SoC control group. https://www.candeltx.com/platforms/ https://www.candeltx.com/platforms/"
X Link 2024-11-21T14:54Z [---] followers, [---] engagements

"For men with localized #ProstateCancer treatment decisions are complex. While active surveillance prevents over-treatment in low-risk cases many see progression over time. We're exploring new approaches to bridge this gap through our phase 2b trial. https://www.candeltx.com/pipeline/ https://www.candeltx.com/pipeline/"
X Link 2024-11-22T15:00Z [---] followers, [---] engagements

"Candel is proud to participate in #Movember supporting vital awareness for men's health initiatives. This cause resonates deeply with our mission as we advance our clinical trials in prostate cancer treatment. #MensHealth #ProstateCancer $CADL https://us.movember.com/ https://us.movember.com/"
X Link 2024-11-29T15:00Z [---] followers, [----] engagements

"Our comprehensive clinical development program for CAN-2409 in localized #ProstateCancer includes: - Phase 2b in low-to-intermediate: [---] patients enrolled - Phase [--] in intermediate-high risk: [---] patients enrolled $CADL https://www.candeltx.com/pipeline/ https://www.candeltx.com/pipeline/"
X Link 2024-12-04T15:34Z [---] followers, [----] engagements

"We're pleased to share recent coverage highlighting our phase 2b and phase [--] prostate cancer clinical trials and anticipated data readouts. These trials represent key milestones as we advance novel treatments for cancer patients. $CADL https://www.proactiveinvestors.com/companies/news/1061802/candel-therapeutics-is-pushing-for-a-paradigm-shift-in-cancer-treatment-1061802.html https://www.proactiveinvestors.com/companies/news/1061802/candel-therapeutics-is-pushing-for-a-paradigm-shift-in-cancer-treatment-1061802.html"
X Link 2024-12-06T16:00Z [---] followers, [----] engagements

"A new article by our CEO @paulpetertak MD PhD FMedSci explores transforming clinical trials for prostate cancer through patient-focused endpoints and innovative trial design. Read more: #ProstateCancer $CADL https://www.clinicalleader.com/doc/what-s-needed-to-transform-clinical-trials-in-early-stage-prostate-cancer-0001 https://www.clinicalleader.com/doc/what-s-needed-to-transform-clinical-trials-in-early-stage-prostate-cancer-0001"
X Link 2024-12-10T16:48Z [---] followers, [----] engagements

"Our CMO Garrett Nichols M.D. M.S. discusses our phase [--] trial of CAN-2409 - potentially the first new treatment for localized prostate cancer in decades. Watch: #ProstateCancer $CADL https://www.youtube.com/watchv=iv3HFVKsunM https://www.youtube.com/watchv=iv3HFVKsunM"
X Link 2024-12-10T21:02Z [---] followers, [----] engagements

"Were proud to announce topline data from our pivotal P3 trial investigating CAN-2409 in intermediate-high risk localized prostate cancer a key milestone in our mission to develop innovative treatment options for cancer patients. See the results: $CADL https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-announces-can-2409-achieved-primary-endpoint https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-announces-can-2409-achieved-primary-endpoint"
X Link 2024-12-11T15:46Z [---] followers, [----] engagements

"As [----] draws to a close we're grateful for our team partners & the patients who inspire us. Wishing everyone a peaceful holiday season & continued hope in advancing cancer treatment. #BiotechCommunity #Innovation $CADL"
X Link 2024-12-23T15:00Z [---] followers, [----] engagements

"2024 brought positive topline data readouts for our phase [--] prostate cancer clinical trial and encouraging results across our pipeline. As we welcome [----] we're energized by our progress in advancing novel cancer treatments. Here's to continuing our mission in the new year"
X Link 2025-01-02T15:00Z [---] followers, [----] engagements

"#ICYMI Our phase [--] trial of CAN-2409 met its primary endpoint in localized #ProstateCancer cancer showing significant improvement in disease-free survival. This could be the first major advancement for this indication in decades. @FierceBiotech: $CADL https://www.fiercebiotech.com/biotech/candel-burns-bright-phase-3-prostate-cancer-win-sends-stock-200 https://www.fiercebiotech.com/biotech/candel-burns-bright-phase-3-prostate-cancer-win-sends-stock-200"
X Link 2025-01-07T17:36Z [---] followers, [----] engagements

"Entering [----] with strong momentum Successes in [----] include positive P3 data for CAN-2409 in prostate cancer & encouraging survival data in pancreatic cancer & NSCLC. We remain focused on advancing viral immunotherapies to help patients fight cancer. https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-provides-corporate-update-and-highlights https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-provides-corporate-update-and-highlights"
X Link 2025-01-13T13:05Z [---] followers, [----] engagements

"Our enLIGHTEN Discovery Platform represents a revolutionary step forward in viral immunotherapy development. This systematic data-driven platform combines advanced analytics with human biology to create precisely engineered HSV-based gene constructs. https://www.candeltx.com/platforms/ https://www.candeltx.com/platforms/"
X Link 2025-01-16T15:15Z [---] followers, [----] engagements

"ICYMI: In [----] we successfully completed our public offering raising $92M to advance our cancer treatment pipeline including BLA preparation for CAN-2409 in prostate cancer. Thank you for supporting our mission #BiotechNews $CADL https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-announces-closing-public-offering-and-full https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-announces-closing-public-offering-and-full"
X Link 2025-01-23T15:09Z [---] followers, [---] engagements

"ICYMI: We're starting [----] with strong momentum & clear direction. Our lead candidate CAN-2409 shows promising phase [--] results in prostate cancer. We're advancing toward BLA submission with clear momentum and $103M to fund operations into Q1 [----]. $CADL https://www.proactiveinvestors.com/companies/news/1064164/candel-therapeutics-advancing-lead-candidate-targeting-prostate-cancer-towards-fda-submission-1064164.html https://www.proactiveinvestors.com/companies/news/1064164/candel-therapeutics-advancing-lead-candidate-targeting-prostate-cancer-towards-fda-submission-1064164.html"
X Link 2025-02-04T17:55Z [---] followers, [----] engagements

"Fireside chat: Our CEO @paulpetertak discusses CAN-2409's positive phase [--] results in prostate cancer and Candel's full oncology pipeline with HCW Research Analyst Vernon Bernardino. View here: #CancerResearch #BioTech $CADL https://ir.candeltx.com/events/event-details/hc-wainwright-home-fireside-chat-w-dr-paul-peter-tak-ceo-candel-therapeutics https://ir.candeltx.com/events/event-details/hc-wainwright-home-fireside-chat-w-dr-paul-peter-tak-ceo-candel-therapeutics"
X Link 2025-02-18T15:30Z [---] followers, [----] engagements

"This #CancerPreventionMonth we recognize the importance of research education and community support in the fight against cancer. As we develop new therapeutic options we stand with patients healthcare providers and researchers united to transform cancer care"
X Link 2025-02-20T14:30Z [---] followers, [----] engagements

"Investigational medicine CAN-3110 is breaking new ground in treating high-grade glioma. Engineered to target cancer cells while protecting healthy brain tissue with promising clinical activity in a phase 1b clinical trial. $CADL https://www.candeltx.com/platforms/ https://www.candeltx.com/platforms/"
X Link 2025-02-26T15:41Z [---] followers, [----] engagements

"Today we announced our Q1 [----] financial results and provided corporate updates on our development programs. Full details: $CADL https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-reports-first-quarter-2025-financial-results https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-reports-first-quarter-2025-financial-results"
X Link 2025-05-13T12:12Z [---] followers, [----] engagements

"The FDA has granted RMAT designation to CAN-2409 for localized prostate cancer in patients with intermediate-to-high-risk disease expediting development & review. This supports our path toward BLA submission anticipated for end of [----]. $CADL https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-receives-fda-regenerative-medicine-advanced https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-receives-fda-regenerative-medicine-advanced"
X Link 2025-05-28T12:18Z [---] followers, [----] engagements

"Last week we announced the appointment of Maha Radhakrishnan M.D. to our Board of Directors Maha brings 20+ years of biotech leadership experience in product development & commercialization. #Leadership #CancerTherapeutics $CADL https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-appoints-maha-radhakrishnan-md-its-board https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-appoints-maha-radhakrishnan-md-its-board"
X Link 2025-06-11T15:00Z [---] followers, [---] engagements

"We're pleased to announce Charles Schoch as our new CFO His understanding of our business will be instrumental as we advance our clinical pipeline prepare for BLA submission for CAN-2409 in localized prostate cancer and execute on corporate goals. https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-appoints-charles-schoch-chief-financial https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-appoints-charles-schoch-chief-financial"
X Link 2025-06-23T12:09Z [---] followers, [----] engagements

"We're pleased to announce a $15M registered direct offering to advance pre-commercialization activities for CAN-2409 in prostate cancer. Supported by existing institutional investors and company leadership as we work to transform cancer treatment. https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-announces-15-million-registered-direct https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-announces-15-million-registered-direct"
X Link 2025-06-24T13:17Z [---] followers, [----] engagements

"We're pleased to be added to multiple Russell Value indexes in [----] reconstitution including Russell [----] Value Small Cap Value [----] Value Microcap Value & 3000E Value indexes. We also maintained our membership in the Russell [----] Index. $CADL https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-expands-russell-index-presence-addition https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-expands-russell-index-presence-addition"
X Link 2025-07-09T15:30Z [---] followers, [----] engagements

"#ICYMI @BradLoncar at @BiotechTV and our CEO @paulpetertak discussed CAN-2409's phase [--] prostate cancer data and our strategy across multiple solid tumors at #ASCO25 Watch: https://www.biotechtv.com/post/candel-therapeutics-asco-2025 https://www.biotechtv.com/post/candel-therapeutics-asco-2025"
X Link 2025-07-22T15:30Z [---] followers, [---] engagements

"Our CEO @paulpetertak will present at the 44th Annual Canaccord Genuity Growth Conference. Be sure to connect with us if you're attending the conference. $CADL https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-present-canaccord-genuity-45th-annual-growth https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-present-canaccord-genuity-45th-annual-growth"
X Link 2025-08-11T14:30Z [---] followers, [----] engagements

"Today we announced our financial results and provided corporate updates on our development programs. Progress on our BLA preparations for CAN-2409 in prostate cancer and updates on our financial position as we execute on key value-creating milestones. https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-reports-second-quarter-2025-financial https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-reports-second-quarter-2025-financial"
X Link 2025-08-14T14:42Z [---] followers, [---] engagements

"Excited to announce Carl H. June MD CAR-T cell immunotherapy pioneer has joined Candels Research Advisory Board Dr. Junes expertise in immunotherapy for cancer will be invaluable as we advance our viral immunotherapy programs. $CADL https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-appoints-renowned-immunotherapy-pioneer-carl https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-appoints-renowned-immunotherapy-pioneer-carl"
X Link 2025-09-02T12:25Z [---] followers, [---] engagements

"Were presenting our phase [--] CAN-2409 localized prostate cancer trial at #ASTRO2025 with a subanalysis focused on type of radiation therapy used in the trial. #ProstateCancer #ClinicalData #RadiationOncology https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-presents-phase-3-clinical-trial-can-2409 https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-presents-phase-3-clinical-trial-can-2409"
X Link 2025-09-29T12:08Z [---] followers, [----] engagements

"Its Brain Tumor Awareness Week. Our CAN-3110 program targets recurrent high-grade glioma with oncolytic HSV approach. We are working hard to advance treatment options for challenging brain cancers. $CADL #BrainTumorAwareness"
X Link 2025-10-28T16:01Z [---] followers, [----] engagements

"Our enLIGHTEN platform uses #AI to design cancer immunotherapies. At #SITC2025 were presenting data in models of breast cancer showing this therapy achieved: - 60% tumor suppression - 2.7x increase in CD8+ T cells - Synergistic immune activation https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-showcases-immunotherapy-leadership-sitc-2025 https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-showcases-immunotherapy-leadership-sitc-2025"
X Link 2025-11-07T14:00Z [---] followers, [---] engagements

"November is Movember a global movement raising awareness for mens health. Our CAN-2409 program for localized prostate cancer is advancing toward a Biologics License Application submission to the FDA in Q4 [----] following positive phase [--] results. https://candeltx.com/patients/#step-22 https://candeltx.com/patients/#step-22"
X Link 2025-11-10T15:00Z [---] followers, [---] engagements

"We are seeing steady advancement across our pipeline and look forward to continued momentum as we head into [----]. Learn about the Q3 progress and anticipated plans for the rest of the year in the Q3 [----] financial press release: $CADL https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-reports-third-quarter-2025-financial-results https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-reports-third-quarter-2025-financial-results"
X Link 2025-11-13T13:32Z [---] followers, [----] engagements

"Our CSO is presenting at @BSI_CIPN on leveraging tertiary lymphoid structures to remodel the tumor microenvironment and how AI-driven methods like Multi-Omics Factor Analysis are revealing immune network complexity & associations with clinical outcome. https://virtual.oxfordabstracts.com/event/75153/submission/897 https://virtual.oxfordabstracts.com/event/75153/submission/897"
X Link 2025-11-24T15:01Z [---] followers, [---] engagements

"We are thrilled to be a Scrip Awards finalist in TWO categories: - Best Oncology R&D Advance (CAN-2409 phase [--] in prostate cancer) - Biotech Company of the Year - Developmental Stage Thank you @Citeline for the recognition $CADL https://www.citeline.com/en/awards/scripawards https://www.citeline.com/en/awards/scripawards"
X Link 2025-11-25T17:49Z [---] followers, [----] engagements

"Happening Today: Our Virtual R&D Day Weve gathered leading experts to explore Candels viral immunotherapy approach to cancer. The discussion will include insights into our CAN-2409 and CAN-3110 pipeline. Register now: $CADL https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-host-virtual-rd-event-december-5-2025 https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-host-virtual-rd-event-december-5-2025"
X Link 2025-12-05T13:03Z [---] followers, [---] engagements

"Were thrilled to announce that Candel has been honored at the Scrip Awards [----] This recognition celebrates our successful phase [--] study of CAN-2409 in localized prostate cancer. Thank you to @Citeline for this honor. https://www.citeline.com/en/awards/scripawards https://www.citeline.com/en/awards/scripawards"
X Link 2025-12-12T13:34Z [---] followers, [----] engagements

"Dr. Aggarwal presented data from Candels phase2a trial of CAN-2409 in non-small cell lung cancer at the World Conference on Lung Cancer. The trial reveals promising results for patients with immune checkpoint inhibitor (ICI)-refractory disease. @IASLC: https://www.ilcn.org/can-2409-plus-valacyclovir-extends-survival-in-ici-refractory-nsclc/ https://www.ilcn.org/can-2409-plus-valacyclovir-extends-survival-in-ici-refractory-nsclc/"
X Link 2025-12-18T15:00Z [---] followers, [---] engagements

"2026 brings renewed energy and purpose. Our [----] milestones have set the stage for transformative advancements as we step into the new year committed to our mission of developing novel cancer treatments that offer real hope to patients. #HappyNewYear"
X Link 2026-01-01T15:00Z [---] followers, [---] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing